Halozyme Therapeutics Inc (HALO)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 363,821 | 83,808 | 169,798 | 196,953 | 151,047 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $363,821K)
= 0.00
Halozyme Therapeutics Inc has consistently reported a debt-to-capital ratio of 0.00 over the years from December 31, 2020, to December 31, 2024. This implies that the company has been financing its operations mainly using its equity capital rather than debt financing. A debt-to-capital ratio of 0.00 indicates that the company has no debt in its capital structure, which could be perceived positively by investors and creditors as it signifies lower financial risk and reliance on external borrowing. This low ratio suggests that Halozyme Therapeutics Inc may have a strong financial position and may be less vulnerable to financial distress related to debt obligations. However, it is essential to consider other financial ratios and factors alongside the debt-to-capital ratio to gain a comprehensive understanding of the company's overall financial health and risk profile.
Peer comparison
Dec 31, 2024